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SUMMARY
In this case, a thirty six year old patient on treatment for schizophrenia is described 
with severe tardive dyskinesia. The most likely cause is long term treatment with 
two highly potent typical antipsychotic medications. The patient was initially treated 
with Benzhexol, an anticholinergic agent with the potential to induce or aggravate the 
disorder. This case discusses the common presentation and management of neuroleptic 
induced tardive dyskinesia.
INTRODUCTION
In the resource constrained setting of most African 
healthcare facilities, conventional antipsychotic 
medications are widely used in managing most 
psychotic illnesses. Their wide use has been 
attributed to their easy availability and low cost 
(1). These antipsychotic drugs are characterised 
by good efficacy, but are associated with a high 
risk for extrapyramidal side effects which include 
acute dystonia, acute akathasia (subjective and 
objective restlessness) and medication induced 
Parkinsonism. In addition, they carry a 5%  to 7% 
per year cumulative risk of late-onset choreoathetotic 
movements of the orofacial region, neck, trunk, or 
limbs known as tardive dyskinesia (TD) (2). Due to 
their clinical importance, these disorders have been 
included in the text revision of the diagnostic and 
statistical manual of mental disorders fourth edition 
(DSM-IV TR) (3).
 A study carried out at Kenya’s Mathari Hospital 
found a tardive dyskinesia prevalence rate of 11.9% 
among patients using conventional antipsychotics, 
a rate that was thought to be lower than that 
reported in Western countries but similar to that in 
Asian countries (4). In patients on treatment with 
conventional antipsychotics, the development of 
other early extrapyramidal symptoms (dystonia, 
akathasia or Parkinsonism) predicts an increased 
risk for developing tardive dyskinesia (5).
 It is however sometimes difficult to differentiate 
between neuroleptic induced TD and other 
conditions which result in orofacial movements 
such as Huntington’s chorea, Sydenham’s chorea, 
and thyrotoxicosis, or other drugs such as L-Dopa, 
Bromocriptine or amantadine (3).
 In this case report, we present a case of a young 
woman who developed tardive dyskinesia following 
treatment with two antipsychotics with high potential 
for extra pyramidal side effects and the clinical 
approach applied towards treating her condition. 
CASE REPORT
A thirty seven year old Kenyan woman was referred 
from a peripheral hospital to Moi Teaching and 
Referral Hospital (MTRH) in Eldoret with major 
complains of abnormal neck posture for four months 
and involuntary lip smacking, chewing and tongue 
protrusion for a month.  
 She had been on outpatient treatment for 
schizophrenia for the previous seven years at the 
peripheral hospital and was on combination therapy 
with depot haloperidol 50 milligrams given as monthly 
injections and 100 milligrams of chlorpromazine at 
night. At the time of her presentation, she had not 
had any active symptoms of schizophrenia for the 
previous three years.
 Her symptoms were at first mild and intermittent, 
but progressively worsened enough to limit her daily 
activities including feeding, self care and household 
chores and necessitated constant care. At presentation 
she did not have her lower two incisor teeth due to 
an injury she had sustained from a fall from bed as 
a result of the gross involuntary movements. These 
symptoms abated in her sleep. 
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 She was taken to the peripheral hospital and 
admitted one week after the onset of the lip smacking 
and orofacial movements. A diagnosis of bacterial 
meningitis was made, with differential diagnosis 
of tetanus and cerebral malaria. Cerebrospinal fluid 
(CSF) samples for culture and microscopy, a random 
blood sugar and blood slide for malaria parasites 
were done, none of which revealed any pathology. 
Both her liver and renal function test findings were 
essentially within the normal range and so was the 
complete blood count. Treatment was then initiated 
with 2 grams of intravenous ceftriaxone twice daily, 
500 milligrams of intravenous metronidazole eight 
hourly and a stat dose of 0.5 milliliters of tetanus 
toxoid before being referred to MTRH. 
 On admission to MTRH, a diagnosis of catatonic 
schizophrenia was initially made and a head 
computed tomography (CT) scan done to rule out 
intracranial pathology. The antipsychotic medication 
was subsequently stopped and the patient put on 
5 milligrams of Benzhexol and intravenous fluids 
and a psychiatry review was sought. Repeat CSF 
studies, random blood sugars, blood slide for malaria 
parasites and CT scan done upon admission revealed 
no pathology. A diagnosis of tardive dyskinesia was 
made at this point and all the medication including 
the Benzhexol stopped. Treatment was at first with a 
six hourly dose of 10 milligrams diazepam for a week. 
During subsequent psychiatric reviews, her condition 
had not improved and one week later, the dose of 
diazepam was increased to 30 milligrams six hourly. 
 She remained in hospital for a period of two more 
weeks during which no significant improvement was 
noted. She was discharged home to be followed up 
by psychiatry outpatient clinic upon the request of 
her family and she was booked for review two weeks 
after discharge.
DISCUSSION
Dopamine hypersensitivity due to up regulation 
of D2 receptors induced by antipsychotic blockade 
remains the most accepted hypothesis for tardive 
dyskinesia (6). Results from a systematic review 
of eleven long term studies indicate less incidence 
of TD (0.5 to 1%) from newer antipsychotics such 
as olanzapine and quetiapine  compared to the 
conventional antipsychotics such as haloperidol and 
chlorpromazine (7). This has been attributed to the 
lower affinity for dopamine receptors and higher 
affinity for serotonin receptors in the newer agents 
compared to the conventional ones (6). Other than 
the medication used, studies indicate that additional 
risk factors for TD include old age, a long duration 
of treatment, indiscriminate use of anticholinergic 
medication and female sex (8). 
 The diagnostic criteria for tardive dyskinesia 
includes at least four weeks of symptoms of movement 
disorder following use of antipsychotic medication 
for a minimum duration of three months (3). The 
simultaneous use of two or more antipsychotic 
medication in management of schizophrenia 
is controversial (7). The practice is difficult to 
justify pharmacologically, since the antipsychotic 
effectiveness of all of these agents appears to be related 
to the same dopaminergic receptor system (6). The 
overall advantage of combination therapy in terms 
of suppressing the active symptoms and improving 
prognosis compared to single therapy with individual 
medication has not been clearly elucidated.
 The onset and course of TD is variable. At first, 
the symptoms are mild and may not be easily noticed 
except to a keen observer. At this stage, the disorder 
is almost completely reversible by complete cessation 
of the medication (4). As the symptoms progress, 
they tend to become more permanent in nature, this 
may reflect a greater degree of injury to the basal 
ganglia. If the individual with tardive dyskinesia 
remains off medication, the dyskinesia remits within 
three months in one-third of the cases and by 12-18 
months in more than 50% of cases, although these 
percentages are lower in older persons (6). 
 Although tardive dyskinesia following long-
term antipsychotic therapy has been recognised 
for many years, treatment remains unsatisfactory. 
Treatments such as vitamin E, benzodiazepines, and 
clozapine and branched-chain amino acids have been 
used, but none has been shown to be superior or 
effective (9). Indeed, the role of benzodiazepines in 
managing medication induced TD is not clear. In a 
Cochrane review involving three large scale studies, 
no clear change in eventual outcome was reported 
following the use of either of three benzodiazepines, 
clonazepam, lorazepam and diazepam (10). At 
the time of discharge, the patient still had active 
symptoms of TD but her eventual outcome is not 
known since she did not return for her follow-up 
appointment.
In conclusion, this paper has presented a case of 
tardive dyskinesia, which presented a diagnostic 
and management challenge to clinicians both at a 
peripheral health facility and at a teaching and referral 
hospital in Western Kenya. It is important for clinicians 
to maintain a high index of suspicion in all patients 
on antipsychotic medications who develop movement 
disorders, and differentiating tardive dyskinesia 
from other movement disorders is important in 
determining the appropriate management.
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